Text Size

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

This study has been terminated.
(Low accrual)
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00609739
First received: February 6, 2008
Last updated: January 31, 2012
Last verified: January 2012
History of Changes
Results First Received: November 22, 2011  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Leukemia
Interventions: Drug: cyclosporine
Drug: cytarabine
Drug: filgrastim
Drug: methotrexate
Drug: methylprednisolone
Drug: mitoxantrone hydrochloride
Procedure: allogeneic bone marrow transplantation
Procedure: umbilical cord blood transplantation
Drug: Cis-Retinoic acid

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Cytarabine + Mitoxantrone Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.

Participant Flow:   Overall Study
    Cytarabine + Mitoxantrone  
STARTED     1  
COMPLETED     1  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Cytarabine + Mitoxantrone Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.

Baseline Measures
    Cytarabine + Mitoxantrone  
Number of Participants  
[units: participants]
 		  1  
Age  
[units: years]
 		 
<=18 years     1  
Between 18 and 65 years     0  
>=65 years     0  
Gender  
[units: participants]
 		 
Female     1  
Male     0  
Region of Enrollment  
[units: participants]
 		 
United States     1  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Disease-free Survival   [ Time Frame: 1 year ]
  Show Outcome Measure 1

2.  Secondary:   Patients With Regimen-Related Toxicity   [ Time Frame: Up to 30 Days Post Study Treatment ]
  Show Outcome Measure 2

3.  Secondary:   Patients With Graft-Versus-Host-Disease   [ Time Frame: Up to 30 Days Post Study Treatment ]
  Show Outcome Measure 3

4.  Secondary:   Patients Who Relapsed   [ Time Frame: 1 Year ]
  Show Outcome Measure 4


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.  


Results Point of Contact:  
Name/Title: Margaret MacMillan, M.D.
Organization: Masonic Cancer Center, University of Minnesota
phone: 612-626-2778
e-mail: macmi002@umn.edu


No publications provided


Responsible Party: Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier: NCT00609739     History of Changes
Other Study ID Numbers: 1999LS032, UMN-MT1999-08, 9906M07303
Study First Received: February 6, 2008
Results First Received: November 22, 2011
Last Updated: January 31, 2012
Health Authority: United States: Food and Drug Administration